Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test

Neuropharmacology

Volumn 54, Issue 3, 2008, Pages 577-587

  Gould, Todd D ^a   O'Donnell, Kelley C ^a   Dow, Eliot R ^a   Du, Jing ^a   Chen, Guang ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alpha amino 3 hydroxy 5 methyl 4 isoxazole propionic acid (AMPA); Antidepressant; Bipolar disorder; Depression; Forced swim test (FST); Glutamate; Lithium; Mood stabilizer; Tail suspension test (TST)

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; LITHIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL SURFACE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; EXPERIMENTAL TEST; FORCED SWIMMING TEST; HIPPOCAMPUS; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIL SUSPENSION TEST; WESTERN BLOTTING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; INJECTIONS, INTRAVENTRICULAR; LITHIUM; MICE; MICE, INBRED C57BL; PROTEIN TRANSPORT; QUINOXALINES; RECEPTORS, AMPA; SWIMMING; TIME FACTORS;

EID: 38649109833     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.11.002     Document Type: Article

References (78)

1. Alt A., Nisenbaum E.S., Bleakman D., and Witkin J.M. A role for AMPA receptors in mood disorders. Biochem. Pharmacol. 71 (2006) 1273-1288
2. Antonelli T., Ferioli V., Lo Gallo G., Tomasini M.C., Fernandez M., O'Connor W.T., Glennon J.C., Tanganelli S., and Ferraro L. Differential effects of acute and short-term lithium administration on dialysate glutamate and GABA levels in the frontal cortex of the conscious rat. Synapse 38 (2000) 355-362
3. Bai F., Li X., Clay M., Lindstrom T., and Skolnick P. Intra- and interstrain differences in models of "behavioral despair". Pharmacol. Biochem. Behav. 70 (2001) 187-192
4. Bai F., Bergeron M., and Nelson D.L. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 44 (2003) 1013-1021
5. Barbon A., Popoli M., La Via L., Moraschi S., Vallini I., Tardito D., Tiraboschi E., Musazzi L., Giambelli R., Gennarelli M., Racagni G., and Barlati S. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol. Psychiatry 59 (2006) 713-720
6. Bauer M.S., and Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am. J. Psychiatry 161 (2004) 3-18
7. Bauer M., Forsthoff A., Baethge C., Adli M., Berghofer A., Dopfmer S., and Bschor T. Lithium augmentation therapy in refractory depression-update 2002. Eur. Arch. Psychiatry Clin. Neurosci. 253 (2003) 132-139
8. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5099-5104
9. Bersudsky Y., Shaldubina A., and Belmaker R.H. Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav. Pharmacol. 18 (2007) 77-80
10. Black M.D. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl.) 179 (2005) 154-163
11. Bleakman D., Alt A., and Witkin J.M. AMPA receptors in the therapeutic management of depression. CNS Neurol. Disord. Drug Targets 6 (2007) 117-126
12. Bonanno G., Giambelli R., Raiteri L., Tiraboschi E., Zappettini S., Musazzi L., Raiteri M., Racagni G., and Popoli M. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 25 (2005) 3270-3279
13. Boudreau A.C., and Wolf M.E. Behavioral sensitization to cocaine is associated with increased AMPA receptor surface expression in the nucleus accumbens. J. Neurosci. 25 (2005) 9144-9151
14. Bourin M., Hascoet M., Colombel M.C., Redrobe J.P., and Baker G.B. Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotoninergic systems. Eur. Neuropsychopharmacol. 6 (1996) 231-236
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
16. Chapman A.G., Smith S.E., and Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 9 (1991) 92-96
17. Cryns K., Shamir A., Shapiro J., Daneels G., Goris I., Van Craenendonck H., Straetemans R., Belmaker R.H., Agam G., Moechars D., and Steckler T. Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology 32 (2007) 881-891
18. de Montigny C., Cournoyer G., Morissette R., Langlois R., and Caille G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch. Gen. Psychiatry 40 (1983) 1327-1334
19. Dixon J.F., and Hokin L.E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8363-8368
20. Dixon J.F., Los G.V., and Hokin L.E. Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-d-aspartate receptor in monkey and mouse cerebral cortex slices. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8358-8362
21. Du J., Gray N.A., Falke C.A., Chen W., Yuan P., Szabo S.T., Einat H., and Manji H.K. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J. Neurosci. 24 (2004) 6578-6589
22. Du J., Suzuki K., Wei Y., Wang Y., Blumenthal R., Chen Z., Falke C., Zarate Jr. C.A., and Manji H.K. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32 (2007) 793-802
23. Eroglu L., and Hizal A. Antidepressant action of lithium in behavioral despair test. Pol. J. Pharmacol. Pharm. 39 (1987) 667-673
24. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., Krishnan K.R., Nemeroff C.B., Bremner J.D., Carney R.M., Coyne J.C., Delong M.R., Frasure-Smith N., Glassman A.H., Gold P.W., Grant I., Gwyther L., Ironson G., Johnson R.L., Kanner A.M., Katon W.J., Kaufmann P.G., Keefe F.J., Ketter T., Laughren T.P., Leserman J., Lyketsos C.G., McDonald W.M., McEwen B.S., Miller A.H., Musselman D., O'Connor C., Petitto J.M., Pollock B.G., Robinson R.G., Roose S.P., Rowland J., Sheline Y., Sheps D.S., Simon G., Spiegel D., Stunkard A., Sunderland T., Tibbits Jr. P., and Valvo W.J. Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 58 (2005) 175-189
25. Ghoshdastidar D., Dutta R.N., and Poddar M.K. In vivo distribution of lithium in plasma and brain. Indian J. Exp. Biol. 27 (1989) 950-954
26. Gould T.D., Einat H., Bhat R., and Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7 (2004) 387-390
27. Gould T.D., Einat H., O'Donnell K.C., Picchini A.M., Schloesser R.J., and Manji H.K. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32 10 (2007) 2173-2183
28. Gould T.D., O'Donnell K.C., Picchini A.M., and Manji H.K. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 32 (2007) 1321-1333
29. Gray N.A., Du J., Falke C.S., Yuan P., and Manji H.K. Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo. Ann. NY Acad. Sci. 1003 (2003) 402-404
30. Hall R.A., and Soderling T.R. Quantitation of AMPA receptor surface expression in cultured hippocampal neurons. Neuroscience 78 (1997) 361-371
31. Hascoet M., Bourin M., and Khimake S. Additive effect of lithium and clonidine with 5-HT1A agonists in the forced swimming test. Prog. Neuropsychopharmacol. Biol. Psychiatry 18 (1994) 381-396
32. Hamburger-Bar R., Robert M., Newman M., and Belmaker R.H. Interstrain correlation between behavioural effects of lithium and effects on cortical cyclic AMP. Pharmacol. Biochem. Behav. 24 (1986) 9-13
33. Heninger G.R., Charney D.S., and Sternberg D.E. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch. Gen. Psychiatry 40 (1983) 1335-1342
34. Hokin L.E., Dixon J.F., and Los G.V. A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl-d-aspartate receptor in monkey and mouse cerebral cortex slices. Adv. Enzyme Regul. 36 (1996) 229-244
35. Institute of Laboratory Animal Resources (U.S.). Guide for the Care and Use of Laboratory Animals (1996), National Academy Press, Washington, D.C
36. Jamison K.R. Suicide and bipolar disorder. J. Clin. Psychiatry 61 Suppl. 9 (2000) 47-51
37. Kaidanovich-Beilin O., Milman A., Weizman A., Pick C.G., and Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry 55 (2004) 781-784
38. Karkanias N.B., and Papke R.L. Lithium modulates desensitization of the glutamate receptor subtype gluR3 in Xenopus oocytes. Neurosci. Lett. 277 (1999) 153-156
39. Karkanias N.B., and Papke R.L. Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol. 81 (1999) 1506-1512
40. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., and Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005) 617-627
41. Knapp R.J., Goldenberg R., Shuck C., Cecil A., Watkins J., Miller C., Crites G., and Malatynska E. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol. 440 (2002) 27-35
42. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 293 (2005) 2528-2530
43. Lauterborn J.C., Lynch G., Vanderklish P., Arai A., and Gall C.M. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20 (2000) 8-21
44. Legutko B., Li X., and Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40 (2001) 1019-1027
45. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., and Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40 (2001) 1028-1033
46. Li X., Witkin J.M., Need A.B., and Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell. Mol. Neurobiol. 23 (2003) 419-430
47. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., and Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117 (2003) 697-706
48. Lucki I., Dalvi A., and Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl.) 155 (2001) 315-322
49. Mackowiak M., O'Neill M.J., Hicks C.A., Bleakman D., and Skolnick P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43 (2002) 1-10
50. Maeng, S., Zarate Jr., C.A., Du J., Schloesser, R.J., McCammon, J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry, in press. doi:10.1016/j.biopsych.2007.05.028.
51. Marcus S.R., Nadiger H.A., Chandrakala M.V., Rao T.I., and Sadasivudu B. Acute and short-term effects of lithium on glutamate metabolism in rat brain. Biochem. Pharmacol. 35 (1986) 365-369
52. Martinez-Turrillas R., Frechilla D., and Del Rio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 43 (2002) 1230-1237
53. Martinez-Turrillas R., Del Rio J., and Frechilla D. Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 49 (2005) 1178-1188
54. Martinez-Turrillas R., Del Rio J., and Frechilla D. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem. Biophys. Res. Commun. 353 (2007) 750-755
55. Mayorga A.J., and Lucki I. Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl.) 155 (2001) 110-112
56. Mendels J., Secunda S.K., and Dyson W.L. A controlled study of the antidepressant effects of lithium carbonate. Arch. Gen. Psychiatry 26 (1972) 154-157
57. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 (1997) 2921-2927
58. Monaghan D.T., Yao D., and Cotman C.W. Distribution of [3H]AMPA binding sites in rat brain as determined by quantitative autoradiography. Brain Res. 324 (1984) 160-164
59. Morrison Jr. J.M., Pritchard H.D., Braude M.C., and D'Aguanno W. Plasma and brain lithium levels after lithium carbonate and lithium chloride administration by different routes in rats. Proc. Soc. Exp. Biol. Med. 137 (1971) 889-892
60. + channels in spinal cord neurones. Eur. J. Neurosci. 25 (2007) 445-450
61. Naylor P., Stewart C.A., Wright S.R., Pearson R.C., and Reid I.C. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Brain Res. Mol. Brain Res. 35 (1996) 349-353
62. Nixon M.K., Hascoet M., Bourin M., and Colombel M.C. Additive effects of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system. Psychopharmacology (Berl.) 115 (1994) 59-64
63. O'Brien W.T., Harper A.D., Jove F., Woodgett J.R., Maretto S., Piccolo S., and Klein P.S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
64. O'Donnell K.C., and Gould T.D. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci. Biobehav. Rev. 31 (2007) 932-962
65. Petit-Demouliere B., Chenu F., and Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl.) 177 (2005) 245-255
66. Pittaluga A., Bonfanti A., and Raiteri M. Differential desensitization of ionotropic non-NMDA receptors having distinct neuronal location and function. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997) 29-38
67. Pittaluga A., Raiteri L., Longordo F., Luccini E., Barbiero V.S., Racagni G., Popoli M., and Raiteri M. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 53 (2007) 27-36
68. Razoux F., Garcia R., and Lena I. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology 32 (2007) 719-727
69. Redrobe J.P., and Bourin M. Effects of pretreatment with clonidine, lithium and quinine on the activities of antidepressant drugs in the mouse tail suspension test. Fundam. Clin. Pharmacol. 11 (1997) 381-386
70. Ripoll N., David D.J., Dailly E., Hascoet M., and Bourin M. Antidepressant-like effects in various mice strains in the tail suspension test. Behav. Brain Res. 143 (2003) 193-200
71. Schou M. Lithium treatment at 52. J. Affect. Disord. 67 (2001) 21-32
72. Shaldubina A., Johanson R.A., O'Brien W.T., Buccafusca R., Agam G., Belmaker R.H., Klein P.S., Bersudsky Y., and Berry G.T. SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol. Genet. Metab. 88 (2006) 384-388
73. Souza F.G., and Goodwin G.M. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br. J. Psychiatry 158 (1991) 666-675
74. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.) 85 (1985) 367-370
75. Sullivan P.F., Neale M.C., and Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157 (2000) 1552-1562
76. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., and Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3182-3187
77. Wang J.K., Andrews H., and Thukral V. Presynaptic glutamate receptors regulate noradrenaline release from isolated nerve terminals. J. Neurochem. 58 (1992) 204-211
78. Zarate Jr. C.A., Singh J., and Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59 (2006) 1006-1020